HIGHLIGHTS
- who: Chia-Yi Tian from the (UNIVERSITY) have published the research work: Pembrolizumab-induced myasthenia gravis-like disorder, ocular myositis, and hepatitis: a case report, in the Journal: (JOURNAL)
SUMMARY
Pembrolizumab and other immune checkpoint inhibitors are the emerging treatment for selected, high-grade malignancies. As a result, enhanced cytotoxic T_cells can recognize tumor cells and induce cellular death. Immune checkpoint inhibitors (ICI) such as cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed cell death 1 (PD-1), and programmed cell death ligand 1 (PD-L1) are increasingly prevalent in the treatment of . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.